Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series.

Dağ U, Çağlayan M, Öncül H, Alakuş MF

International ophthalmology15 Jul 2020Cited by 2 (Europe PMC)

PMID32671599DOI10.1007/s10792-020-01501-6PepBankPUB-32671599

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesSafety outcome
In bodybuilding athletes, CSCR followed high-dose follistatin‑344 injections in 11 patients, with unilateral disease in ten and bilateral disease in one.
In plain wordsIn bodybuilding athletes, follistatin‑344 injections preceded CSCR in 11 patients, affecting one eye in ten and both eyes in one.
Peptide
Follistatin-344
Outcome
Not applicableCentral serous chorioretinopathy
Study
n = 11
Outcome group
Adverse events · Eye
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
Patients with unilateral CSCR
10 patients
at diagnosis after high-dose follistatin-344 injections
Patients with bilateral CSCR
1 patient
at diagnosis after high-dose follistatin-344 injections
Source sentences
Summary
At the time of diagnosis, ten patients had unilateral CSCR findings and one had bilateral CSCR findings.
4 context sentences(design, population, supporting numbers)
Summary · context
To present 11 bodybuilding athletes who developed central serous chorioretinopathy (CSCR) following high-dose subcutaneous follistatin-344, a peptide-based performance and image enhancing drug, injections to increase muscle mass.
Summary · context
All patients had a history of injecting complete 1 mg vials of follistatin-344 subcutaneously in the abdomen.
Summary · context
This is a retrospective case series from one institution.
Summary · context
Demographic and clinical data of 11 patients who were admitted to our clinic with decreased visual acuity after high-dose follistatin-344 injections and optical coherence tomography (OCT) findings consistent with CSCR were analyzed.
Report a problemFND-3267159901
02HumanCase report or seriesSafety outcome
In eight patients with one previous follistatin‑344 injection, subretinal fluid disappeared after an average of 2.3 ± 0.7 months.
In plain wordsIn eight patients with one follistatin‑344 injection, fluid under the retina disappeared after an average of 2.3 months.
Peptide
Follistatin-344
Outcome
DecreaseSubretinal fluid resolution
Study
n = 8
Outcome group
Adverse events · Eye
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
Time to fluid resolution
2.3 months
single previous injection
Reported ± uncertainty for mean time to fluid resolution
0.7 months
single previous injection; mean 2.3 months; uncertainty type not stated
Source sentences
Summary
In all eight patients with a history of only one injection, subretinal fluid completely disappeared after an average of 2.3 ± 0.7 months and symptoms regressed.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a retrospective case series from one institution.
Summary · context
Demographic and clinical data of 11 patients who were admitted to our clinic with decreased visual acuity after high-dose follistatin-344 injections and optical coherence tomography (OCT) findings consistent with CSCR were analyzed.
Report a problemFND-3267159902
03HumanCase report or seriesSafety outcome
In eight patients with one previous follistatin‑344 injection, CSCR symptoms regressed.
In plain wordsIn eight patients with one follistatin‑344 injection, CSCR symptoms decreased.
Peptide
Follistatin-344
Outcome
DecreaseCSCR symptoms
Study
n = 8
Outcome group
Adverse events · Eye
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
Patients with regressed CSCR symptoms
8 patients
history of only one follistatin-344 injection
Source sentences
Summary
In all eight patients with a history of only one injection, subretinal fluid completely disappeared after an average of 2.3 ± 0.7 months and symptoms regressed.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a retrospective case series from one institution.
Summary · context
Demographic and clinical data of 11 patients who were admitted to our clinic with decreased visual acuity after high-dose follistatin-344 injections and optical coherence tomography (OCT) findings consistent with CSCR were analyzed.
Report a problemFND-3267159903
04HumanCase report or seriesSafety outcome
In three patients with multiple previous follistatin‑344 injections, recurrent CSCR developed.
In plain wordsIn three patients with repeated follistatin‑344 injections, CSCR recurred.
Peptide
Follistatin-344
Outcome
Not applicableRecurrent CSCR
Study
n = 3
Outcome group
Adverse events · Eye
Studied dose
1 mg · subcutaneousAs given in this study (human).
Measurements
Patients with recurrent CSCR
3 patients
history of multiple follistatin-344 injections
Source sentences
Summary
Recurrent CSCR developed in three patients with a history of multiple follistatin-344 injections.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a retrospective case series from one institution.
Summary · context
Demographic and clinical data of 11 patients who were admitted to our clinic with decreased visual acuity after high-dose follistatin-344 injections and optical coherence tomography (OCT) findings consistent with CSCR were analyzed.
Report a problemFND-3267159904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.